Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- Device: Fundus Photography
- Registration Number
- NCT05806957
- Lead Sponsor
- Ophthalytics, Inc.
- Brief Summary
Multicenter, prospective, study to assess the performance of the Ophthal-360 platform in the diagnosis of more-than-mild Diabetic Retinopathy (mtmDR) in diabetic patients with no previous diagnosis of DR.
- Detailed Description
This is a multicenter, prospective study in which 500 adult subjects at risk for DR but never before diagnosed who satisfy all entry criteria will be enrolled at up to 5 primary care sites.
An additional sub-study will be performed on 30 subjects to assess the precision of the algorithm in detecting DR by imaging these subjects multiple times to demonstrate intra- and inter-operator reliability of the algorithm.
All enrolled subjects will undergo retinal imaging by a novice operator with no experience using the fundus cameras listed. Images from each retinal imaging device will be saved to a computer and uploaded to the server for evaluation by the Ophthal-360 service. A report will be generated and archived for the results of each image.
After imaging by the novice operator, each patient will then have their eyes photographed by a professional fundus photographer using standard mydriatic and OCT imaging for macular edema evaluation. These images will be sent to a Fundus Photography Reading Center for final determination and diagnosis. Patients will received the result of the FPRC evaluation, but not be provided the reports generated by the software.
A comparison between the FPRC determination and the software generated report will be performed to evaluate the analytical performance of the algorithm.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
-
Aged at least 22 years old.
-
A documented history of Diabetes Mellitus, defined as any of the following:
- Hemoglobin A1c (HbA1c) ≥ 6.5% based on repeated assessments
- Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) based on repeated assessments
- Oral Glucose Tolerance test with 2-hour plasma glucose ≥ 200 mg/dL (11.1mmol/L) using equivalent of 75g anhydrous glucose dose in water.
- Symptoms of hyperglycemia or hyperglycemic crisis with random plasma glucose ≥ 200mg/dL (11.1 mmol/L)
- Criteria established by either the World Health Organization (WHO) or the American Diabetes Association (ADA).
-
Willing to undergo fundus photography by up to 4 different methods and/or cameras.
-
Has signed a written informed consent form prior to study participation.
-
Diagnosed with uncorrectable vision loss (e.g., with the use of eyeglasses), blurred vision, or floaters.
-
Diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion.
-
Has a positive history for laser treatment of the retina or injections into either eye, or any history of retinal surgery.
-
Is currently participating in another investigational eye study and actively receiving investigational product for DR or Diabetic Macular Edema (DME).
-
Has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation).
-
Is contraindicated for imaging by fundus imaging systems used in the study:
- hypersensitive to light
- recently (within 6 months) underwent photodynamic therapy (PDT)
- taking medication that causes photosensitivity
- positive history for angle-closure glaucoma or narrow anterior chamber angles
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Device: Color Fundus Photography with Non-Mydriatic and Mydriatic Cameras Fundus Photography -
- Primary Outcome Measures
Name Time Method Specificity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images 1 day Performance of the Ophthal-360 Software when compared to ground truth evaluation of fundus photographs by qualified experts.
Sensitivity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images 1 day Performance of the Ophthal-360 Software when compared to results of evaluation of fundus photographs by qualified experts.
- Secondary Outcome Measures
Name Time Method